You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR METHYLERGONOVINE MALEATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for METHYLERGONOVINE MALEATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00891150 ↗ Oxytocin to Decrease Blood Loss During Cesarean Section Completed American University of Beirut Medical Center N/A 2012-07-01 The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.
NCT02408965 ↗ Uterotonic Prophylaxis Trial Completed University of California, San Francisco Phase 4 2015-03-01 Excessive bleeding after dilation and evacuation (D&E) requiring interventions is common, occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic prophylaxis at the time of D&E, particularly with methylergonovine maleate (MM), is a common practice among D&E providers despite nearly no evidence for its efficacy. Finding ways to decrease excessive bleeding after D&E has the potential both to improve patient safety and to reduce costs of provider-initiated interventions. The investigators propose a randomized, controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing excessive bleeding measured by a composite outcome among women undergoing D&E at 20 to 24 weeks.
NCT03303235 ↗ Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections Withdrawn Johns Hopkins University Early Phase 1 2020-07-01 Insufficient uterine tone resulting in atony can potentiate hemorrhage and adverse outcomes for the parturient. Oxytocin is the first pharmacologic agent used, followed by methylergonovine, carboprost, and misoprostol. The American Congress of Obstetricians and Gynecologists (ACOG) recommends the sequential use of oxytocin, followed by methylergonovine, carboprost, misoprostol, then surgical intervention for cases of refractory uterine atony. Many studies have examined the effect and dosage of intravenous uterotonics, including oxytocin. Although there are anecdotal reports of using intravenous bolus or rapid infusion of methylergonovine, no randomized trial has compared efficacy and side effects of these two routes of administration. Investigators hypothesize that intravenous methylergonovine reduces the time to adequate uterine tone (the tone at which the uterus is adequately contracted to prevent atony after delivery of neonate), decreases the total dose of methylergonovine to contract the uterus, and therefore produces fewer side effects of hypertension, nausea, and vomiting. Reducing the time to achieve adequate uterine tone is likely to decrease postpartum hemorrhage.
NCT03584854 ↗ Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial Recruiting Brigham and Women's Hospital Phase 4 2019-03-01 The aim of this study is to evaluate in a randomized fashion the comparative efficacy of two second-line medications, methylergonovine and carboprost for treating atonic postpartum hemorrhage (PPH). The investigators hypothesize that administration of methylergonovine will produce superior uterine tone to carboprost in atonic PPH.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for METHYLERGONOVINE MALEATE

Condition Name

Condition Name for METHYLERGONOVINE MALEATE
Intervention Trials
Postpartum Hemorrhage 2
Uterine Atony 2
Uterine Tone Disorders 1
Complications; Cesarean Section 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for METHYLERGONOVINE MALEATE
Intervention Trials
Hemorrhage 4
Uterine Inertia 2
Postpartum Hemorrhage 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for METHYLERGONOVINE MALEATE

Trials by Country

Trials by Country for METHYLERGONOVINE MALEATE
Location Trials
United States 3
Lebanon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for METHYLERGONOVINE MALEATE
Location Trials
Massachusetts 1
Maryland 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for METHYLERGONOVINE MALEATE

Clinical Trial Phase

Clinical Trial Phase for METHYLERGONOVINE MALEATE
Clinical Trial Phase Trials
Phase 4 2
N/A 1
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for METHYLERGONOVINE MALEATE
Clinical Trial Phase Trials
Completed 2
Recruiting 1
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for METHYLERGONOVINE MALEATE

Sponsor Name

Sponsor Name for METHYLERGONOVINE MALEATE
Sponsor Trials
Brigham and Women's Hospital 1
American University of Beirut Medical Center 1
University of California, San Francisco 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for METHYLERGONOVINE MALEATE
Sponsor Trials
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.